Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-972-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 02 June 1992 to 22 September 1992
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 999
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- Deviations:
- not specified
- Principles of method if other than guideline:
- A 13-week toxicity study in B6C3F1 mice was conducted to evaluate the effects of repeated dermal exposure to the test substance.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- (9Z)-N,N-bis(2-hydroxyethyl)octadec-9-enamide
- EC Number:
- 700-972-2
- Molecular formula:
- C22H43NO3
- IUPAC Name:
- (9Z)-N,N-bis(2-hydroxyethyl)octadec-9-enamide
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: Taconic Farms (Germantown, NY)
- Age at study initiation: 8 wk
- Housing: Housed individually in polycarbonate cages
-Method of distribution: Animals were distributed randomly into groups of approximately equal initial mean body weights.
- Bedding: Sani-Chip® heat-treated hardwood chips (PJ Murphy Forest Products Corp., Montville, NJ), changed weekly
- Diet: NIH-07 open formula pelleted diet (Zeigler Brothers, Inc., Gardners, PA), available ad libitum
- Water: Tap water (Columbus municipal supply) via automatic watering system (Edstrom Industries, Inc., Waterford, WI), available ad libitum
- Acclimation period:Time held before studies: Males: 21 d and Females: 22 d
- Cages: Polycarbonate (Lab Products, Inc., Maywood, NJ), changed weekly and rotated every 2 wks
- Animal number per cage: 1
- Cage Filters: Spun-bonded polyester Du Pont 2024 (Snow Filtration, Co., Cincinnati, OH), changed every 2 wks
- Racks: Stainless steel drawer-type (Lab Products, Inc., Maywood, NJ), changed and rotated every 2 wks
ENVIRONMENTAL CONDITIONS
- Temperature: 20.6-25.6°C
- Relative humidity: 39-65 %
- Air changes: 10/h
- Photoperiod: 12 h dark/12 h light
IN-LIFE DATES: From: 1992-06-02 To: 1992-09-22
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- ethanol
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The dose formulations were prepared every 3 weeks by mixing the test substance by stirring or sonicating with 95% ethanol to give the required concentrations. The test substance formulations were applied on shaved skin of the test animals.
- Storage of dose formulations: The dose formulations were stored at room temperature, protected from light, in amber glass bottles for up to 28 days.
- Stability studies of a 10 mg/mL formulation prepared from lot CH1F980 (not used) were performed by the study laboratory using high-performance liquid chromatography. Stability of the dose formulation was confirmed for at least 28 days when stored in sealed containers, protected from ultraviolet light, at up to room temperature or for 3 hours when stored open to air and light. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Periodic analyses of the dose formulations of the test substance from the beginning, middle, and end of the study were analyzed using HPLC. All the samples from the formulations analyzed during the 13 week study were within 10% of the target concentration.
- Stability of dose formulations: Stability was confirmed for at least 28 days when stored in sealed containers, protected from ultraviolet light, at up to room temperature or for 3 hours when stored open to air and light - Duration of treatment / exposure:
- 13 wks
- Frequency of treatment:
- 5 exposures/wk
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 400 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 800 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10/sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Method of animal grouping: Distributed randomly into groups of approximately equal initial mean body weights.
Examinations
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Clinical findings were recorded weekly
BODY WEIGHT: Yes
- Time schedule for examinations: Weighed initially, weekly, and again at the end of the study
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
OTHER: Organs weighed were heart, right kidney, liver, lung, right testis, and thymus - Sacrifice and pathology:
- SACRIFICE: At the end of the 13-week study animals were sacrificed by carbon dioxide asphyxiation.
GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes.
- Complete histopathology was performed on 0 and 800 mg/kg bw/day mice. In addition to gross lesions and tissue masses, the tissues examined were: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, heart, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, liver, lung, lymph nodes (mandibular and mesenteric), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, spleen, stomach (forestomach and glandular), testis (and epididymis and seminal vesicle), thymus, thyroid gland, trachea, urinary bladder, and uterus. In addition, the skin was examined in all mice.
- All major tissues were fixed and preserved in 10% neutral buffered formalin processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6 μm, and stained with hematoxylin and eosin for microscopic examination. - Other examinations:
- Sperm motility and vaginal cytology:
- Samples were collected for sperm motility or vaginal cytology from all mice in the 0, 200, 400, and 800 mg/kg bw/day dose groups.
- The sperm motility parameters evaluated was: Sperm concentration, sperm motility, sperm count, spermatid heads per testis, and spermatid heads per gram of testis. The left cauda, epididymis, and testis were weighed.
- Vaginal samples were collected for 12 consecutive days prior to the end of the studies for vaginal cytology evaluations. The parameters evaluated were: the length of the estrous cycle and the length of time spent in each stage of the cycle. - Statistics:
- Statistical analyses for possible dose-related effects on survival used Cox’s (1972) method for testing two groups for equality and Tarone’s (1975) life table test to identify dose-related trends.
- Analysis of neoplasm and non-neoplastic lesion incidences: The Poly-k test (Bailer and Portier, 1988; Portier and Bailer, 1989; Piegorsch and Bailer, 1997) was used to assess neoplasm and nonneoplastic lesion prevalence. Tests of significance included pair wise comparisons of each dosed group with controls and a test for an overall dose-related trend. Continuity-corrected tests were used in the analysis of lesion incidence, and reported P values are one sided. Values of P greater than 0.5 are presented as 1-P with the letter N added to indicate a lower incidence or negative trend in neoplasm occurrence relative to the control group (e.g., P=0.99 is presented as P=0.01N).
- Analysis of Continuous Variables: Organ and body weight data were analysed using the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). Hematology, clinical chemistry, spermatid, and epididymal spermatozoal data were analyzed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey. Average severity values were analyzed for significance with the Mann-Whitney U test (Hollander and Wolfe, 1973). Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976) to the transformed data to test for simultaneous equality of measurements across dose levels.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Clinical findings included irritation of the skin at the site of application. Irritation occurred in all surviving dosed males and in most females administered 100 mg/kg bw or greater; time of onset was inversely related to dose. Irritation progressed to ulcer in one 800 mg/kg bw male.
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- Occurred at the site of application in all dosed males and in most of the females administered ≥100 mg/kg bw/day. Irritation progressed to ulcer in one male in the 800 mg/kg bw/day dose group.
- Mortality:
- no mortality observed
- Description (incidence):
- All animals except one male mice at 800 mg/kg bw/day survived until the end of the study.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced final mean body weights and body weight gains of males at 800 and females at ≥400 mg/kg bw/day.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - Increased absolute and relative heart weights of males at 400 and 800 mg/kg bw/day and of females at ≥200 mg/kg bw/day. Further, the absolute heart weights were increased for females in ≥50 mg/kg bw/day dose groups.
- Increased liver weights in all dosed groups
- Increased kidney weights of males at ≥50 mg/kg bw/day.
- Decreased absolute thymus weight of males at ≥200 mg/kg bw/day and of females at ≥400 mg/kg bw/day. Decreased relative thymus weight was observed with females only the 800 mg/kg bw/day dosed groups. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- - Skin: Dose dependent increase in the incidences of lesions (including epidermal hyperplasia, parakeratosis, suppurative epidermal inflammation, chronic active dermal inflammation, sebaceous gland hypertrophy, and ulcer in males and females) were observed.
- Bone marrow myeloid hyperplasia in males and females at 800 mg/kg bw/day and increased hematopoietic cell proliferation of spleen in males at 800 mg/kg bw/day and in females at 400 and 800 mg/kg bw/day were observed. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
- Description (incidence and severity):
- Sperm motility and vaginal cytology parameters of dosed mice were similar to those of the vehicle controls.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- (systemic effects)
- Effect level:
- ca. 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Altered organ weights (with increased liver weights in all dosed groups) and reduced body weights and body weight gains at 800 mg/kg bw/day in males and ≥400 mg/kg bw/day in females
- Key result
- Dose descriptor:
- LOAEL
- Remarks:
- (local effects)
- Effect level:
- 50 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Irritation of the skin at the site of application in all dosed males and in most of the females administered ≥100 mg/kg bw/day.
Target system / organ toxicity
- Key result
- Critical effects observed:
- not specified
Any other information on results incl. tables
For detailed results table kindly refer to the attached background materials section of the IUCLID.
Applicant's summary and conclusion
- Conclusions:
- Under the study conditions, the 13-week LOAEL for both systemic and local effects was considered to be 50 mg/kg bw/day.
- Executive summary:
A study was conducted to evaluate the repeated dose dermal toxicity in B6C3F1 mice of the test substance, C18-unsatd. DEA, according to design based on OECD Guidance 411, in compliance with GLP. Groups of 10 male and 10 female mice were dermally exposed to 0, 50, 100, 200, 400 or 800 mg/kg bw/day in ethanol at a frequency of 5 d/week for a period of 13 weeks. Mortality, clinical findings, body weight and histopathology were evaluated at specific time intervals. All male and female mice except one 800 mg/kg bw/day male survived until the end of the study. Final mean body weights and body weight gains of 800 mg/kg bw/day males and females and 400 mg/kg bw/day females were significantly lower than those of the vehicle controls. Clinical findings in dosed mice included irritation of the skin at the site of application. Irritation occurred in all surviving dosed males and in most females administered ≥100 mg/kg bw/day. The heart weights of 400 and 800 mg/kg bw/day males and females and 200 mg/kg bw/day females and the kidney weights of 50, 100, and 400 mg/kg bw/day males were significantly greater than those of the vehicle controls. Relative to the vehicle controls, the liver weights were increased in all dosed groups. A dose-dependent increase in the incidences of non-neoplastic skin lesions included epidermal hyperplasia, parakeratosis, suppurative epidermal inflammation, chronic active dermal inflammation, sebaceous gland hypertrophy and ulcer. Under the study conditions, the 13-week LOAEL for both systemic and local effects was considered to be 50 mg/kg bw/day (NTP, 1999).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.